Navigation Links
BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
Date:11/8/2012

LYNBROOK, N.Y., Nov. 8, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the third quarter ended September 30, 2012 and provided a corporate update.

"We are very happy with the ongoing clinical development progress for our XIAFLEX pipeline, including the recent submission of a sBLA filing by our partner Auxilium for the potential treatment of Peyronie's disease," said Thomas L. Wegman, President of BioSpecifics. "Additionally, Auxilium recently completed enrollment in its cellulite Phase Ib and frozen shoulder Phase IIa studies and began enrollment for its 600 patient label expansion study for Dupuytren's contracture patients with multiple palpable cords. We look forward to reporting top-line data from each of these studies in the fourth quarter of 2012, the first quarter of 2013 and the first half of 2014, respectively. We also anticipate that we will complete enrollment in our internally-managed human and canine lipoma Phase II trials during the first half of 2013. In addition, we are very encouraged by the ongoing commercial initiatives Auxilium has implemented to continue to expand XIAFLEX sales for Dupuytren's contracture in the U.S."

Third Quarter 2012 Financial Results
BioSpecifics reported net income of $0.5 million for the third quarter ended September 30, 2012, or $0.07 per basic and diluted common share, compared to a net income of $0.3 million, or $0.04 per basic and diluted common share, for the same period in 2011.

Total revenue for the third quarter of 2012 was $2.4 million, compared to $1.9 million for the same period in 2011.

Royalty, mark-up on cost of goods sold, and earn-out revenues for the third quart
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
3. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
4. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Patient Safety Technologies Reports Third Quarter 2012 Results
7. Life Technologies Announces Third Quarter 2012 Results
8. Life Technologies Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to Thursday, November 1, 2012 Due To Expected Severe Weather Conditions
9. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
10. $1 Million Global B.R.A.I.N. Prize Announced by Israel Brain Technologies
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... Calif. , May 23, 2013 ... a strategic alliance with DAK Renewable Research to ... corn oil yield. VG Energy is a majority ... Pink: VGLS). VG Energy,s exclusively licensed ... increase the oil yield in plants, possessing a ...
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... which bounced to a near pinpoint landing inside a ... seven-month flight, promises a trove of new data about ... a UW-Madison professor of geology and geophysics who has ... Mars, expects the latest mission to add considerably to ...
... Wis. - GE Medical Systems and University Community Health ... based in Tampa, Florida have announced an agreement to build ... Medical Systems will be the technology provider for UCH's ... Southeast using advanced digital technology, when it opens in the ...
... has many great assets for building a thriving high technology ... at the University of Wisconsin-Madison . Yet we ... we have lacked one vital ingredient: venture capital to support ... ,According to the National Venture Capital Association , Wisconsin, ...
Cached Biology Technology:GE Medical Enables Digital Heart Hospital 2GE Medical Enables Digital Heart Hospital 3Wisconsins VC Challenge 2Wisconsins VC Challenge 3
(Date:5/24/2013)... 24, 2013 A frequently expressed concern in the ongoing ... fresh vegetables, especially those that are nutrient dense. ... and Beans Provide Most Nutrients Per Penny," published in ... are one of the best nutritional values in the ... per penny than most other raw vegetables and delivering ...
(Date:5/24/2013)... detection and destruction by the immune system. Stimulation of ... however, there are many factors that cause the immune ... immune cells that function to suppress the immune system ... Clinical Investigation , researchers led by Ronald Levy at ... tumors express proteins that can be targeted with therapeutic ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
Breaking Biology News(10 mins):New research shows that potatoes provide one of the best nutritional values per penny 2A new strategy required in the search for Alzheimer's drugs? 2
... scientists start analyzing it), but it is fascinating. As we ... a sperm, a whole lot of cell division and growth, ... mix of genes from both parents. There are many startling ... and important is the transition from unfertilized egg to fertilized ...
... our planet, consisting of only DNA or RNA and a ... second most common type of organism. In our oceans they ... a better understanding of the structure and characteristics of these ... be able to determine their masses and how much these ...
... drug has been shown to improve blood flow in diseased ... attacks, a Monash University study published today reveals. , The ... in conjunction with Bayer Health Care, hopes to use the ... heart disease. , Dr. Harald Schmidt, Director of the Centre ...
Cached Biology News:Cracking the egg 2Weighty viruses 2Heart smart: new drug improves blood flow 2
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
Argon Calibration Source...
SHEEP ANTI ESCHERICHIA COLI...
Recombinant Rat Leptin, CF...
Biology Products: